Former President Donald Trump's recent comments advocating for higher housing prices have ignited debate, as experts warn such a stance could deepen the affordability crisis for younger generations and renters.
A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.
Abbott Laboratories moves to acquire cancer-testing leader Exact Sciences in a landmark deal, signaling a strategic shift toward high-growth diagnostics while simultaneously restructuring its challenged Nutrition business.
Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.
Fifth Third Bancorp has finalized its $12.3 billion acquisition of Comerica Bank, with customer system conversions and branch rebranding scheduled to begin after Labor Day. The deal reshapes Michigan's banking landscape and creates the nation's ninth-largest bank.
London's blue-chip index surged to a historic high as investors rotated into defensive sectors, shrugging off a brutal sell-off in precious metals and oil triggered by geopolitical shifts and regulatory moves.
As inflation persists, Baby Boomers are leveraging decades of financial experience to cut costs strategically. We examine the key spending categories they avoid and the generational mindset behind their money choices.
Sugar futures extended their sharp decline this week, with London white sugar hitting a five-year low, as robust harvests from Brazil and India signal a prolonged period of ample global supplies.
Morgan Stanley's top strategist argues that recent U.S. trade shifts have prompted nations worldwide to reassess and leverage their own economic strengths, creating a multi-year investment opportunity in a more multipolar global order.
A new study reveals the cost gap between Waymo's driverless vehicles and human-driven Uber and Lyft rides is shrinking, signaling a pivotal moment for the competitive robotaxi industry.
After a sharp January sell-off, Shopify's stock is hovering near a significant long-term trendline—a level that has preceded notable rallies in the past.
CNBC's Jim Cramer expressed reservations about aviation services provider AAR Corp., highlighting its 15% gross yield as a potential red flag for investors during a recent market analysis segment.
CNBC's Jim Cramer reaffirmed his bullish stance on Palantir Technologies during a recent 'Mad Money' segment, placing the data analytics firm in the same league as established giants like ServiceNow and Salesforce.
CNBC's Jim Cramer concedes he misjudged the explosive demand for Apple's iPhone 17, which powered the tech giant to a staggering earnings beat that caught Wall Street off guard.
CNBC's Jim Cramer expressed renewed bullishness on Tesla, shifting focus from its electric vehicle business to its ambitions in robotics and autonomous 'Cybercab' technology following the company's latest earnings call.
Business Facilities magazine has named North Carolina its 'State of the Year' for business climate and economic development, the state's third such win in six years, following a surge of multi-billion dollar investments from tech and manufacturing giants.
Personal finance icon Suze Orman echoes a timeless principle from Napoleon Hill's 'Think and Grow Rich': the battle for wealth is won or lost in the mind. Experts argue that self-doubt, not market conditions, is the primary barrier most people face.
The rapid adoption of algorithmic decision-making in UK banks has created a critical lag in oversight and accountability structures, leaving institutions exposed to risks that traditional governance models are ill-equipped to manage.
Wall Street analysts have issued a revised price target for Lucid Group (LCID), reflecting updated assessments of the electric vehicle maker's execution risks, funding runway, and demand trajectory. The shift underscores the evolving narrative around the company's ability to scale amid intense competition and macroeconomic headwinds.
BioNTech's stock faces pressure following a Leerink Partners downgrade, which tempered near-term optimism around its oncology pipeline after a recent rally. The move highlights investor reassessment of catalysts amid mixed long-term performance.
